Recommendations for medical management of hereditary breast and ovarian cancer: The INSERM-FNCLCC ad hoc committee;Expertise collective INSERM-FNCLCC: Recommandations portant sur la prise en charge des femmes ayant un risque d'origine genetique de developper un cancer du sein et/ou de l'ovaire

Annales d'Endocrinologie

Volumn 59, Issue 6, 1998, Pages 470-484

  Eisinger, F ^a   Alby, N ^b   Bremond, A ^c   Dauplat, J ^d   Espie M ^e   Janiaud, P ^a   Kuttenn, F ^f   Lebrun, J P ^d   Lefranc, J P ^g   Pierret, J ^h   Sobol, H ^a   Stoppa Lyonnet, D ⁱ   Thouvenin, D ^d   Tristant, H ^d   Feingold, J ^a  

^a INSERM   (France)

^b Ligue Nationale Contre le Cancer   (France)

^c CENTRE LÉON BÉRARD   (France)

^d Department des Université CRLCC Clermont Jean Perrin ^*

^e UNIVERSITÉ PARIS DESCARTES   (France)

^f HÔPITAL NECKER ENFANTS MALADES   (France)

^g PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^h CNRS   (France)

ⁱ INSTITUT CURIE   (France)

Author keywords

BRCA1; BRCA2; Breast Cancer; Guidelines; Ovarian Cancer; Preventive care

Indexed keywords

ANTINEOPLASTIC AGENT; CA 125 ANTIGEN; HORMONE; TUMOR MARKER;

BREAST CANCER; BREAST EXAMINATION; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CANCER THERAPY; CONFERENCE PAPER; FAMILIAL CANCER; FAMILY PLANNING; GENE MUTATION; HORMONAL REGULATION; HUMAN; IMAGING; MASTECTOMY; MEDICAL EXPERT; ONCOGENE; OVARIECTOMY; OVARY CANCER; TREATMENT INDICATION; TREATMENT PLANNING;

EID: 0032443949     PISSN: 00034266     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (13)

1. AMERICAN COLLEGE of PHYSICIANS. Guidelines for Counseling Postmenopausal Women about Preventive Hormone Therapy. Ann Intern Med 1992; 117: 1038-41.
2. AUVINEN A, ELOVAINIO L, HAKAMA M. Breast self examination and surviival from breast cancer. A prospective follow-up study. Breast Cancer Res Treat 1996 ; 38 : 161-8.
3. BIESECKER BB, BOEHNKE M, CALZONE K, MARKEL DS, GARBER JE, COLLINS FS et al. Genetic counseling for families with inherited susceptibility to breast and ovarian cancer. Jama 1993 ; 269 : 1970-4.
4. CASEY M, BEWTRA C, GARCIA-PADIAL J, LYNCH H. Laparascopic examination and assisted bilateral salpingo-oophorectomy hysterectomy for prophylactic removal of the ovaries and uterus in women at genetic risk for ovarian cancer. J Gynecol Tech 1995 ; 1 : 111-4.
5. CLAUS EB, SCHILDKRAUT JM, THOMPSON JM, RISCH NJ. The Genetic Attribuable Risk of Breast and Ovarian Cancer. Cancer 1996 ; 77: 2318-24.
6. COLDITZ G, ROSNER B, SPEIZER F, GROUP FtNHSR. Risk Factors for Breast Cancer According to Family History of Breast Cancer. J Natl Cancer Inst 1996; 88: 365-71.
7. COLDITZ GA, GIOVANNUCCI E, GRODSTEIN F, HANKINSON S, HENNEKENS C, HUNTER D et al. Oral contraceptive use and mortality during 12 years of follow-up : The nurses'health study. Ann Intern Med 1994; 120: 821-6.
8. COLLABORATIVE GROUP ON HORMONAL FACTORS is BREAST CANCER. Breast cancer and hormonal contraceptives : collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet 1996 ; 347 : 1713-27.
9. COUCH F, FARID L, DESHANO M, TAGVITIAN S, CAZONE K, CAMPEAU L et al. BRCA2 germline mutations in male breast cancer cases and breast cancer families. Nature Genetics 1996 ; 13 : 123-5.
10. COUCH F, WEBER B, THE BREAST CANCER et al. Mutations and polymorphisms in the familial early-onset breast cancer (BRCA1) gene. Human Mutation 1996 ; 8 : 8-18.
11. COUCH FJ, DESHANO ML, BLACKWOOD MA, CALZONE K, STOPFER J, CAMPEAU L et al. BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N Engl J Med 1997 ; 336 : 1409-15.
12. DE VATHAIRE F, REZVANI A, LAPLANCHE A, ESTÈVE J, FERLAY J, editors. Estimation de l'incidence des cancers en France 1983-1987. Paris : Editions INSERM; 1996.
13. DEN OTTER W, MERCHANT T, BEIJERINCK, KOTEN J. Breast Cancer Induction due to Mammographic Screening in Hereditary Affected Women. Anticancer Res 1996 ; 16 : 3173-6.